

Paul C Lorigan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6642459/publications.pdf>

Version: 2024-02-01

248
papers

50,751
citations

13865

67
h-index

1461

220
g-index

256
all docs

256
docs citations

256
times ranked

41502
citing authors

#	ARTICLE	IF	CITATIONS
1	Reasons for using indoor tanning devices: A systematic review of qualitative evidence. British Journal of Health Psychology, 2023, 28, 22-46.	3.5	5
2	T cell immune awakening in response to immunotherapy is age-dependent. European Journal of Cancer, 2022, 162, 11-21.	2.8	5
3	Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600E Mutant Unresectable or Metastatic Melanoma. Journal of Clinical Oncology, 2022, 40, 1428-1438.	1.6	90
4	Circulating Tumour DNA in Melanoma—Clinic Ready?. Current Oncology Reports, 2022, 24, 363-373.	4.0	10
5	Cost-effectiveness of a policy-based intervention to reduce melanoma and other skin cancers associated with indoor tanning*. British Journal of Dermatology, 2022, 187, 105-114.	1.5	12
6	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. Journal of Clinical Oncology, 2022, 40, 1068-1080.	1.6	43
7	Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nature Medicine, 2022, 28, 535-544.	30.7	158
8	Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities. European Journal of Cancer, 2022, 164, 62-69.	2.8	4
9	Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma. British Journal of Cancer, 2022, 126, 1450-1456.	6.4	0
10	Prognostic and predictive value of β -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. European Journal of Cancer, 2022, 165, 97-112.	2.8	18
11	Stratification of radiosensitive brain metastases based on an actionable <i>S100A9</i> /RAGE resistance mechanism. Nature Medicine, 2022, 28, 752-765.	30.7	30
12	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. European Journal of Cancer, 2022, 170, 256-284.	2.8	92
13	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. Journal of Clinical Oncology, 2022, 40, 3741-3749.	1.6	33
14	Oxidative stress from DGAT1 oncoprotein inhibition in melanoma suppresses tumor growth when ROS defenses are also breached. Cell Reports, 2022, 39, 110995.	6.4	19
15	Reply to E. Hindi. Journal of Clinical Oncology, 2021, 39, 944-946.	1.6	1
16	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 655-664.	10.7	37
17	Sunbed Use among 11- to 17-Year-Olds and Estimated Number of Commercial Sunbeds in England with Implications for a "Buy-Back" Scheme. Children, 2021, 8, 393.	1.5	7
18	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 643-654.	10.7	224

#	ARTICLE	IF	CITATIONS
19	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 836-847.	10.7	104
20	The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. <i>Nature Communications</i> , 2021, 12, 4098.	12.8	80
21	Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. <i>International Journal of Cancer</i> , 2021, 149, 1926-1934.	5.1	8
22	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply. <i>Lancet Oncology</i> , The, 2021, 22, e343-e344.	10.7	2
23	Patient engagement in melanoma research: from bench to bedside. <i>Future Oncology</i> , 2021, 17, 3705-3716.	2.4	5
24	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2021, 158, 156-168.	2.8	19
25	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. <i>JAMA Oncology</i> , 2020, 6, 519.	7.1	287
26	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3925-3936.	1.6	192
27	Brain microenvironment-driven resistance to immune and targeted therapies in acral melanoma. <i>ESMO Open</i> , 2020, 5, e000707.	4.5	3
28	Adjuvant immunotherapy: the sting in the tail. <i>European Journal of Cancer</i> , 2020, 132, 207-210.	2.8	20
29	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , 2020, 130, 126-138.	2.8	84
30	Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy. <i>Nature Cancer</i> , 2020, 1, 210-221.	13.2	138
31	Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma. <i>Nature Communications</i> , 2020, 11, 853.	12.8	23
32	Emergency presentations in patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020, 130, 193-197.	2.8	33
33	Survival of patients with early invasive melanoma down-staged under the new eighth edition of the American Joint Committee on Cancer staging system. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 272-274.	1.2	11
34	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1239-1251.	10.7	812
35	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 121, 144-153.	2.8	27
36	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 119, 168-178.	2.8	61

#	ARTICLE	IF	CITATIONS
37	Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. <i>European Journal of Cancer</i> , 2019, 116, 207-215.	2.8	35
38	Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop. <i>Annals of Oncology</i> , 2019, 30, 1038-1040.	1.2	11
39	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019, 116, 148-157.	2.8	64
40	Enhanced Fatty Acid Scavenging and Glycerophospholipid Metabolism Accompany Melanocyte Neoplasia Progression in Zebrafish. <i>Cancer Research</i> , 2019, 79, 2136-2151.	0.9	24
41	An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. <i>European Journal of Cancer</i> , 2019, 107, 175-185.	2.8	13
42	Management of Chronic Hypotony Following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 1012-1015.	1.8	13
43	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1789-1801.	27.0	1,441
44	The role of nivolumab in melanoma. <i>Future Oncology</i> , 2018, 14, 1241-1252.	2.4	12
45	Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. <i>Oncoimmunology</i> , 2018, 7, e1433516.	4.6	31
46	Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. <i>European Journal of Cancer</i> , 2018, 91, 116-124.	2.8	69
47	Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. <i>ESMO Open</i> , 2018, 3, e000317.	4.5	12
48	Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 87-96.	6.3	89
49	Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 582-590.	4.7	51
50	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. <i>European Journal of Cancer</i> , 2018, 91, 168-170.	2.8	33
51	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 383-390.	1.6	431
52	Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-223249.	0.5	11
53	Emergency management of immune-related hypophysitis: Collaboration between specialists is essential to achieve optimal outcomes. <i>Cancer</i> , 2018, 124, 4731-4731.	4.1	4
54	25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. <i>British Journal of Cancer</i> , 2018, 119, 793-800.	6.4	11

#	ARTICLE	IF	CITATIONS
55	Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. <i>Annals of Oncology</i> , 2018, 29, 1843-1852.	1.2	47
56	Surrogate endpoints in advanced sarcoma trials: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 34617-34627.	1.8	9
57	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 226-235.	1.6	458
58	Does adjuvant ipilimumab have little adverse effect on quality of life?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 395-396.	27.6	5
59	Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. <i>Lancet Oncology</i> , The, 2017, 18, 1116-1125.	10.7	415
60	Reply to “Comment on “Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy””. <i>British Journal of Cancer</i> , 2017, 116, e15-e15.	6.4	1
61	Survival of patients with advanced metastatic melanoma: the impact of novel therapies—update 2017. <i>European Journal of Cancer</i> , 2017, 83, 247-257.	2.8	236
62	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet</i> , The, 2017, 390, 1853-1862.	13.7	1,032
63	The role for chemotherapy in the modern management of melanoma. <i>Melanoma Management</i> , 2017, 4, 125-136.	0.5	26
64	Adjuvant interferon- γ for the treatment of high-risk melanoma: An individual patient data meta-analysis. <i>European Journal of Cancer</i> , 2017, 82, 171-183.	2.8	159
65	Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. <i>Clinical Lung Cancer</i> , 2017, 18, 68-76.e2.	2.6	59
66	Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 651-660.	3.8	5
67	Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). <i>Annals of Translational Medicine</i> , 2017, 5, 390-390.	1.7	0
68	Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9501-9501.	1.6	6
69	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9524-9524.	1.6	17
70	Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 651-660.	3.8	7
71	Nivolumab in treating advanced melanoma. <i>British Journal of Health Care Management</i> , 2016, 22, 294-296.	0.2	0
72	Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e505-e514.	3.8	10

#	ARTICLE	IF	CITATIONS
73	Protocol for the CONVERT trial—Concurrent ONce-daily VERSus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. <i>BMJ Open</i> , 2016, 6, e009849.	1.9	37
74	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. <i>Drugs</i> , 2016, 76, 925-945.	10.9	123
75	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3740-3748.	1.6	438
76	Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65.	4.4	12
77	Sequential immunotherapy regimens—expect the unexpected. <i>Lancet Oncology</i> , The, 2016, 17, 854-855.	10.7	7
78	Integrating radiation therapy with emerging systemic therapies: Lessons from a patient with cerebral radionecrosis, spinal cord myelopathy, and radiation pneumonitis. <i>Practical Radiation Oncology</i> , 2016, 6, 110-113.	2.1	3
79	Phase I study of IMG901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 290-299.	2.6	55
80	Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. <i>Cancer Discovery</i> , 2016, 6, 286-299.	9.4	208
81	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. <i>European Journal of Cancer</i> , 2016, 53, 125-134.	2.8	137
82	Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e505-e514.	3.8	17
83	Hyponatraemia secondary to nivolumab-induced primary adrenal failure. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, .	0.5	60
84	Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells. <i>Oncotarget</i> , 2016, 7, 81995-82012.	1.8	18
85	Ipilimumab in the real world. <i>Melanoma Research</i> , 2015, 25, 432-442.	1.2	50
86	Dabrafenib and its use in the treatment of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 199-208.	0.5	21
87	Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. <i>Nature Medicine</i> , 2015, 21, 741-750.	30.7	107
88	Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. <i>Lung Cancer</i> , 2015, 88, 117-123.	2.0	49
89	Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma. <i>Cancer Cell</i> , 2015, 27, 85-96.	16.8	188
90	Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncology</i> , The, 2015, 16, 15-17.	10.7	10

#	ARTICLE	IF	CITATIONS
91	The place of PD-1 inhibitors in melanoma management. Lancet Oncology, The, 2015, 16, 873-874.	10.7	7
92	Assessing the impact of diagnosis and the related supportive care needs in patients with cutaneous melanoma. Supportive Care in Cancer, 2015, 23, 779-789.	2.2	42
93	Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2015, 372, 2521-2532.	27.0	4,838
94	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2015, 16, 375-384.	10.7	2,353
95	PD-L1 expression as a potential predictive biomarker. Lancet Oncology, The, 2015, 16, 1285-1287.	10.7	98
96	Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. New England Journal of Medicine, 2015, 372, 30-39.	27.0	2,240
97	Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance. Annals of Oncology, 2015, 26, 33-39.	1.2	57
98	A Phase 3 Randomized, Open-Label Study of Nivolumab (Anti-Pd-1; Bms-936558; Ono-4538) Versus Investigator'S Choice Chemotherapy (Icc) in Patients with Advanced Melanoma After Prior Anti-Ctla-4 Therapy. Annals of Oncology, 2014, 25, v1.	1.2	38
99	High-risk cutaneous melanoma follow-up: time for more intensive surveillance?. Melanoma Management, 2014, 1, 7-10.	0.5	1
100	BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling. Science Signaling, 2014, 7, ra30.	3.6	113
101	Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma. Annals of Oncology, 2014, 25, 2052-2058.	1.2	53
102	Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer. Journal of Clinical Oncology, 2014, 32, 4012-4019.	1.6	276
103	Discrepancies in Cancer Genomic Sequencing Highlight Opportunities for Driver Mutation Discovery. Cancer Research, 2014, 74, 6390-6396.	0.9	33
104	A randomized, openâ€label clinical trial of tasisulam sodium versus paclitaxel as secondâ€line treatment in patients with metastatic melanoma. Cancer, 2014, 120, 2016-2024.	4.1	19
105	Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma. Melanoma Research, 2014, 24, 40-46.	1.2	67
106	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncology, The, 2014, 15, 297-304.	10.7	55
107	DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. Annals of Oncology, 2014, 25, 968-974.	1.2	68
108	Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study. British Journal of Dermatology, 2014, 170, 87-95.	1.5	11

#	ARTICLE	IF	CITATIONS
109	No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients. <i>Molecular Oncology</i> , 2014, 8, 1140-1158.	4.6	47
110	Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 449-58.	4.2	253
111	Phase II Pilot Study of Intravenous High-Dose Interferon With or Without Maintenance Treatment in Melanoma at High Risk of Recurrence. <i>Journal of Clinical Oncology</i> , 2014, 32, 185-190.	1.6	43
112	Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology</i> , The, 2014, 15, 323-332.	10.7	890
113	Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. <i>Lancet Oncology</i> , The, 2014, 15, 620-630.	10.7	96
114	The role of chemotherapy in the modern management of melanoma. <i>Melanoma Management</i> , 2014, 1, 173-184.	0.5	8
115	Vemurafenib-induced nonautoimmune haemolytic anaemia. <i>Melanoma Research</i> , 2014, 24, 418-419.	1.2	2
116	Abstract 3704: Novel panRAF inhibitors active in melanomas that are resistant to BRAF-selective, or BRAF-selective/MEK inhibitor combinations. , 2014, , .		1
117	Abstract CT331: Phase I/II trial of a novel antibody DNA immunotherapy, targeting CD64, in the treatment of Melanoma. , 2014, , .		1
118	A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AGO14699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentialiation. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1191-1199.	2.3	164
119	Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1582-1590.	0.7	122
120	Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 616-622.	1.6	720
121	Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma. <i>Cancer Discovery</i> , 2013, 3, 158-167.	9.4	300
122	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. <i>Lancet Oncology</i> , The, 2013, 14, 733-740.	10.7	151
123	Urgent treatment of patients with metastatic melanoma using braf inhibitors in the absence of braf mutation status. <i>Annals of Oncology</i> , 2013, 24, 1712-1713.	1.2	2
124	Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). <i>Annals of Oncology</i> , 2013, 24, 2694-2698.	1.2	169
125	Phase II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma. <i>British Journal of Cancer</i> , 2013, 109, 1451-1459.	6.4	25
126	Advances in the treatment of late stage melanoma. <i>BMJ</i> , The, 2013, 346, f1265-f1265.	6.0	6

#	ARTICLE	IF	CITATIONS
127	Lenvatinib combined with dacarbazine versus dacarbazine alone as first-line treatment in patients with stage IV melanoma.. Journal of Clinical Oncology, 2013, 31, 9027-9027.	1.6	3
128	DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244); Tj ETQq0 Q Q rgBT /Overlock 10	1.6	0
129	Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.. Journal of Clinical Oncology, 2013, 31, LBA9000-LBA9000.	1.6	5
130	AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence.. Journal of Clinical Oncology, 2013, 31, LBA9000-LBA9000.	1.6	0
131	Systematic Review and Network Meta-Analysis of Overall Survival Comparing 3 mg/kg Ipilimumab With Alternative Therapies in the Management of Pretreated Patients With Unresectable Stage III or IV Melanoma. Oncologist, 2012, 17, 1376-1385.	3.7	23
132	Biomarker analysis in a phase III study of pemetrexed+carboplatin versus etoposide+carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. Annals of Oncology, 2012, 23, 1723-1729.	1.2	27
133	Efficacy of Positron Emission Tomography Staging for Small-Cell Lung Cancer: A Systematic Review and Cost Analysis in the Australian Setting. Journal of Thoracic Oncology, 2012, 7, e25.	1.1	0
134	Authors' reply to Bayley and Cave. BMJ, The, 2012, 345, e5417-e5417.	6.0	0
135	Advances in the management of melanoma: targeted therapy, immunotherapy and future directions. Expert Review of Anticancer Therapy, 2012, 12, 1437-1448.	2.4	24
136	Considerations in developing and delivering a non-pharmacological intervention for symptom management in lung cancer: the views of health care professionals. Supportive Care in Cancer, 2012, 20, 2565-2574.	2.2	20
137	Considerations in Developing and Delivering a Nonpharmacological Intervention for Symptom Management in Lung Cancer: The Views of Patients and Informal Caregivers. Journal of Pain and Symptom Management, 2012, 44, 831-842.	1.2	41
138	Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study). European Journal of Cancer, 2012, 48, 2175-2182.	2.8	39
139	Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health and Quality of Life Outcomes, 2012, 10, 66.	2.4	55
140	Management of Small Cell Lung Cancer. Drugs, 2012, 72, 471-490.	10.9	63
141	Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: A retrospective, longitudinal survey (MELODY study). European Journal of Cancer, 2012, 48, 3205-3214.	2.8	24
142	Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer - Evidence from a phase II trial. Lung Cancer, 2012, 76, 72-77.	2.0	39
143	Applying Best-Worst scaling methodology to establish delivery preferences of a symptom supportive care intervention in patients with lung cancer. Lung Cancer, 2012, 77, 199-204.	2.0	25
144	Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. Lung Cancer, 2012, 78, 276-281.	2.0	25

#	ARTICLE	IF	CITATIONS
145	Identifying melanomas in primary care: can we do better?. BMJ, The, 2012, 345, e4244-e4244.	6.0	6
146	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New England Journal of Medicine, 2012, 367, 107-114.	27.0	1,976
147	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with <i>BRAF</i> ^{V600E} -mutated melanoma.. Journal of Clinical Oncology, 2012, 30, 8502-8502.	1.6	86
148	Anti-Angiogenesis Therapy for Melanoma. , 2012, , 281-294.		0
149	A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.. Journal of Clinical Oncology, 2012, 30, TPS8605-TPS8605.	1.6	1
150	A qualitative exploration of a respiratory distress symptom cluster in lung cancer: Cough, breathlessness and fatigue. Lung Cancer, 2011, 71, 94-102.	2.0	86
151	Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: A multi-institutional retrospective analysis. Lung Cancer, 2011, 72, 378-383.	2.0	56
152	Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group. Lung Cancer, 2011, 73, 338-344.	2.0	4
153	Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. Lung Cancer, 2011, 74, 75-9.	2.0	17
154	The role of positron emission tomography in management of small cell lung cancer. Lung Cancer, 2011, 73, 121-126.	2.0	39
155	Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer â€œEORTC 08062. European Journal of Cancer, 2011, 47, 2322-2330.	2.8	30
156	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine, 2011, 364, 2507-2516.	27.0	6,976
157	A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. British Journal of Cancer, 2011, 104, 750-755.	6.4	113
158	Predicting the myelotoxicity of chemotherapy. Melanoma Research, 2011, 21, 502-508.	1.2	23
159	Survival Benefits from Follow-Up of Patients with Lung Cancer: A Systematic Review and Meta-Analysis. Journal of Thoracic Oncology, 2011, 6, 1993-2004.	1.1	79
160	Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. British Journal of Cancer, 2011, 105, 353-359.	6.4	48
161	A randomised, phase II study of intetumumab, an anti-Î±v-integrin mAb, alone and with dacarbazine in stage IV melanoma. British Journal of Cancer, 2011, 105, 346-352.	6.4	108
162	Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunology, Immunotherapy, 2010, 59, 863-873.	4.2	53

#	ARTICLE	IF	CITATIONS
163	Improving Survival with Thoracic Radiotherapy in Patients with Small Cell Lung Cancer. The CONVERT and the REST Trials. <i>Clinical Oncology</i> , 2010, 22, 547-549.	1.4	8
164	Revised U.K. guidelines for the management of cutaneous melanoma 2010. <i>British Journal of Dermatology</i> , 2010, 163, 238-256.	1.5	343
165	Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma. <i>Clinical Cancer Research</i> , 2010, 16, 1042-1048.	7.0	227
166	Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2598-2603.	1.6	119
167	The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. <i>Annals of Oncology</i> , 2010, 21, 2023-2028.	1.2	91
168	The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit. <i>Annals of Oncology</i> , 2010, 21, 232-237.	1.2	80
169	Revised UK guidelines for the management of cutaneous melanoma 2010. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2010, 63, 1401-1419.	1.0	129
170	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2010, 363, 711-723.	27.0	13,065
171	Lung cancer after treatment for breast cancer. <i>Lancet Oncology</i> , The, 2010, 11, 1184-1192.	10.7	30
172	Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4787-4792.	1.6	176
173	Targeting angiogenesis in melanoma. <i>Expert Review of Dermatology</i> , 2009, 4, 237-248.	0.3	0
174	O6-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. <i>British Journal of Cancer</i> , 2009, 100, 1250-1256.	6.4	40
175	Extensive-stage small-cell lung cancer—moving beyond response rate?. <i>Annals of Oncology</i> , 2009, 20, 801-802.	1.2	3
176	A randomised trial evaluating Bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: An update. <i>Eancermedalscience</i> , 2009, 3, 108.	1.1	7
177	Radiotherapy in Extensive-disease Small Cell Lung Cancer. A Survey of Current UK Practice. <i>Clinical Oncology</i> , 2009, 21, 78.	1.4	4
178	Radiotherapy for small-cell lung cancer—Where are we heading?. <i>Lung Cancer</i> , 2009, 63, 307-314.	2.0	40
179	Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. <i>Lung Cancer</i> , 2009, 64, 60-65.	2.0	24
180	Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. <i>American Journal of Pathology</i> , 2009, 175, 808-816.	3.8	223

#	ARTICLE	IF	CITATIONS
181	Meeting report: consensus from the first and second Global Workshops in Melanoma November 19â€“20, 2008. Pigment Cell and Melanoma Research, 2009, 22, 532-543.	3.3	2
182	Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient. Melanoma Research, 2009, 19, 333-334.	1.2	29
183	Update on targeted therapies for small cell carcinoma of the lung. Targeted Oncology, 2008, 3, 205-215.	3.6	3
184	A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Supportive Care in Cancer, 2008, 16, 201-208.	2.2	100
185	Systemic therapy for metastatic malignant melanoma â€“ from deeply disappointing to bright future?. Experimental Dermatology, 2008, 17, 383-394.	2.9	46
186	Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. British Journal of Cancer, 2008, 99, 442-447.	6.4	43
187	510 POSTER Phase I study of IMG901 (BB-10901) in patients with CD56-positive solid tumours. European Journal of Cancer, Supplement, 2008, 6, 162.	2.2	2
188	Prophylactic cranial irradiation (PCI) in extensive disease (ED) small cell lung cancer (SCLC): an audit of practice. Lung Cancer, 2008, 60, S4.	2.0	1
189	Tarceva in relapsed non-small cell lung cancer: experience from Northwest England. Lung Cancer, 2008, 60, S25-S26.	2.0	0
190	Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet, The, 2008, 372, 117-126.	13.7	620
191	Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial. Expert Review of Anticancer Therapy, 2007, 7, 635-640.	2.4	3
192	Does Adjuvant Vaccine Therapy Really Have Activity in Malignant Melanoma?. Journal of Clinical Oncology, 2007, 25, 4693-4693.	1.6	26
193	Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. Journal of Clinical Oncology, 2007, 25, 3144-3150.	1.6	238
194	Chemotherapy Compared With Biochemotherapy for the Treatment of Metastatic Melanoma: A Meta-Analysis of 18 Trials Involving 2,621 Patients. Journal of Clinical Oncology, 2007, 25, 5426-5434.	1.6	255
195	35 CONVERT-A multicentre randomised controlled NCRN trial comparing accelerated twice-daily and high dose once-daily thoracic radiotherapy in good performance status (PS), limited small-cell lung cancer (LD SCLC) treated concurrently with cisplatin and etoposide. Lung Cancer, 2007, 57, S10.	2.0	0
196	Small Cell Lung Cancer (SCLC); any progress?. European Journal of Cancer, Supplement, 2007, 5, 398-399.	2.2	0
197	Modern Management of Small-Cell Lung Cancer. Drugs, 2007, 67, 2135-2152.	10.9	37
198	Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue. British Journal of Haematology, 2007, 137, 436-442.	2.5	5

#	ARTICLE	IF	CITATIONS
199	Novel Therapies for the Treatment of Small-Cell Lung Cancer. <i>Drugs</i> , 2006, 66, 1919-1931.	10.9	16
200	Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2006, 53, 165-170.	2.0	1
201	Sodium salicylate inhibits TNF- α -induced NF- κ B activation, cell migration, invasion and ICAM-1 expression in human melanoma cells. <i>Melanoma Research</i> , 2006, 16, 11-22.	1.2	27
202	Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2006, 95, 822-828.	6.4	135
203	Re: Small Cell Lung Cancer Treated in Southeast Wales, Lester et al., <i>Clin Oncol</i> 2006;18:378-382. <i>Clinical Oncology</i> , 2006, 18, 722-723.	1.4	0
204	A Review of the Treatment Strategies for Small Cell Lung Carcinoma Patients with a Poor Performance Status. <i>Current Respiratory Medicine Reviews</i> , 2006, 2, 59-66.	0.2	1
205	Melanoma vaccines "they should work. <i>Annals of Oncology</i> , 2006, 17, 539-541.	1.2	3
206	A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). <i>Annals of Oncology</i> , 2006, 17, 1111-1119.	1.2	57
207	Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer: Controversies and Future developments. <i>Clinical Oncology</i> , 2005, 17, 591-598.	1.4	23
208	Randomized Phase II Study of Two Gemcitabine Schedules for Patients With Impaired Performance Status (Karnofsky performance status \geq 70) and Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 2136-2144.	1.6	34
209	Sequential Platinum-Based Chemotherapy-Thoracic Radiotherapy in Early Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5051s-5056s.	7.0	9
210	Randomized Phase III Trial of Dose-Dense Chemotherapy Supported by Whole-Blood Hematopoietic Progenitors in Better-Prognosis Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2005, 97, 666-674.	6.3	85
211	High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia. <i>British Journal of Cancer</i> , 2005, 93, 620-621.	6.4	40
212	Management of small-cell lung cancer. <i>Annals of Oncology</i> , 2005, 16, ii235-ii239.	1.2	35
213	Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. <i>Lancet Oncology</i> , The, 2005, 6, 773-779.	10.7	103
214	O-095 A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small cell lung cancer " A randomised multicentre trial of the British thoracic oncology group (BTOG1). <i>Lung Cancer</i> , 2005, 49, S34.	2.0	0
215	O-153 Phase III randomised trial of doxorubicin based chemotherapy compared with platinum based chemotherapy in both limited and extensive stage patients. <i>Lung Cancer</i> , 2005, 49, S52-S53.	2.0	1
216	Platinum-based chemotherapy with thoracic radiotherapy in stage III good performance status non-small cell lung cancer patients. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 41-50.	2.2	0

#	ARTICLE	IF	CITATIONS
217	Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 576-584.	1.6	403
218	A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2005, 41, 1547-1550.	2.8	12
219	Improving Outcomes in Advanced Malignant Melanoma. <i>Drugs</i> , 2005, 65, 733-743.	10.9	35
220	Thoracic Radiation Therapy for Limited-Stage Small-Cell Lung Cancer: Unanswered Questions. <i>Clinical Lung Cancer</i> , 2005, 7, 23-29.	2.6	22
221	Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant Melanoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 53-61.	1.6	217
222	Palliative treatment. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 417-432.	2.2	2
223	Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant Melanoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 2551-2557.	1.6	108
224	TNF- α increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes. <i>British Journal of Cancer</i> , 2003, 89, 1123-1129.	6.4	75
225	Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma. <i>British Journal of Cancer</i> , 2003, 88, 1335-1338.	6.4	7
226	A Guideline for the Management of Gastrointestinal Stromal Tumour (GIST). <i>Sarcoma</i> , 2002, 6, 83-87.	1.3	10
227	Monitoring tumour cells in the peripheral blood of small cell lung cancer patients. <i>Cytometry</i> , 2002, 50, 160-167.	1.8	56
228	Melanoma Cell Attachment, Invasion, and Integrin Expression is Upregulated by Tumor Necrosis Factor α and Suppressed by α Melanocyte Stimulating Hormone. <i>Journal of Investigative Dermatology</i> , 2002, 119, 1165-1171.	0.7	40
229	Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization. <i>British Journal of Haematology</i> , 2002, 116, 291-298.	2.5	66
230	Fatal Pulmonary Fibrosis Associated with Induction Chemotherapy with Carboplatin and Vinorelbine Followed by CHART Radiotherapy for Locally Advanced Non-small Cell Lung Cancer. <i>Clinical Oncology</i> , 2002, 14, 361-366.	1.4	28
231	Gender and survival in malignant tumours. <i>Cancer Treatment Reviews</i> , 2001, 27, 201-209.	7.7	50
232	Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma. <i>Cancer</i> , 2001, 92, 601-608.	4.1	49
233	Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma. <i>British Journal of Cancer</i> , 2001, 84, 499-503.	6.4	52
234	Oestrogenic Steroids and Melanoma Cell Interaction with Adjacent Skin Cells Influence Invasion of Melanoma Cells In Vitro. <i>Pigment Cell & Melanoma Research</i> , 2000, 13, 68-72.	3.6	9

#	ARTICLE	IF	CITATIONS
235	Guidelines for the Stratification of Patients Recruited to Trials of Therapy for Low-Risk Gestational Trophoblastic Tumor. <i>Gynecologic Oncology</i> , 2000, 78, 92-96.	1.4	13
236	Characteristics of Women with Recurrent Molar Pregnancies. <i>Gynecologic Oncology</i> , 2000, 78, 288-292.	1.4	49
237	Investigation of female survival benefit in metastatic melanoma. <i>British Journal of Cancer</i> , 1999, 80, 2025-2033.	6.4	53
238	Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis. <i>British Journal of Cancer</i> , 1999, 81, 1037-1041.	6.4	21
239	Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , 1999, 35, 410-412.	2.8	67
240	Monitoring neutrophil phagocytosis in lung cancer patients or normal stem cell donors, treated with G-CSF. <i>Biochemical Society Transactions</i> , 1997, 25, 197S-197S.	3.4	1
241	Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate. <i>British Journal of Cancer</i> , 1997, 76, 1382-1386.	6.4	12
242	Gestational choriocarcinoma of the ovary diagnosed by analysis of tumour DNA. <i>Cancer Letters</i> , 1996, 104, 27-30.	7.2	21
243	Current Drug Treatment Guidelines for Epithelial Ovarian Cancer. <i>Drugs</i> , 1996, 51, 571-584.	10.9	15
244	Small cell carcinoma of the cervix. <i>Clinical Oncology</i> , 1996, 8, 102-105.	1.4	13
245	Continuous infusion of 5-fluorouracil with alpha 2b interferon for advanced colorectal carcinoma. <i>British Journal of Cancer</i> , 1995, 72, 193-197.	6.4	2
246	MDR-1 Expression in Non-Hodgkin's Lymphomas is Unrelated to Treatment Intensity or Response to Therapy. <i>Leukemia and Lymphoma</i> , 1995, 18, 297-302.	1.3	8
247	Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation. <i>European Journal of Cancer</i> , 1994, 30, 2085-2090.	2.8	12
248	Septicaemia and septic arthritis due to <i>Pseudomonas putida</i> in a neutropenic patient. <i>Journal of Infection</i> , 1991, 23, 346-347.	3.3	10